Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15942870 | 0.87 | MAPT (0.48) | MAPTGAAHSD17B10RAB9APOLB | |
| SCHEMBL14667394 | 0.85 | USP2 (0.63) | MAPTGAAHSD17B10RAB9ANPC1 | |
| SCHEMBL14667432 | 0.84 | RECQL (0.55) | GAARAB9ANPC1POLBHPGD | |
| SCHEMBL14667397 | 0.83 | ALDH1A1 (0.44) | MAPTALDH1A1HPGDSMN1; SMN2KMT2A | |
| SCHEMBL15942860 | 0.82 | ALOX15 (0.52) | MAPTGAAHSD17B10POLBALDH1A1 | |
| SCHEMBL14667401 | 0.82 | ALOX15 (0.52) | MAPTGAAHSD17B10POLBALDH1A1 | |
| SCHEMBL14667398 | 0.80 | KMT2A (0.60) | MAPTGAARAB9ANPC1TP53 | |
| SCHEMBL15942871 | 0.79 | LMNA (0.43) | MAPTHSD17B10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14667389 | 0.79 | MEN1 (0.47) | MAPTRAB9ANPC1POLBALDH1A1 | |
| SCHEMBL14667441 | 0.79 | HSD17B10 (0.47) | MAPTGAAHSD17B10TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802448-B2 | Mixed mode ligands | PALL CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130030154-A1 | MIXED MODE LIGANDS | PALL CORPORATION (US) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030154-A1 | MIXED MODE LIGANDS | NCL, NECTIN4, NCLN | MAPT 3322/4885GAA 2774/4885HSD17B10 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.